- Home
- ADXN vs BTAI Comparison
ADXN vs BTAI Comparison
Compare ADXN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- BTAI
- Stock Information
- Founded
- ADXN 2002
- BTAI 2017
- Country
- ADXN Switzerland
- BTAI United States
- Employees
- ADXN N/A
- BTAI N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- BTAI Health Care
- Exchange
- ADXN Nasdaq
- BTAI Nasdaq
- Market Cap
- ADXN 8.2M
- BTAI 7.2M
- IPO Year
- ADXN N/A
- BTAI 2018
- Fundamental
- Price
- ADXN $7.45
- BTAI $1.99
- Analyst Decision
- ADXN Strong Buy
- BTAI Buy
- Analyst Count
- ADXN 1
- BTAI 5
- Target Price
- ADXN $30.00
- BTAI $42.60
- AVG Volume (30 Days)
- ADXN 7.7K
- BTAI 1.2M
- Earning Date
- ADXN 04-07-2025
- BTAI 03-27-2025
- Dividend Yield
- ADXN N/A
- BTAI N/A
- EPS Growth
- ADXN N/A
- BTAI N/A
- EPS
- ADXN 0.06
- BTAI N/A
- Revenue
- ADXN $701,260.00
- BTAI $2,266,000.00
- Revenue This Year
- ADXN N/A
- BTAI $105.36
- Revenue Next Year
- ADXN N/A
- BTAI $46.93
- P/E Ratio
- ADXN $0.89
- BTAI N/A
- Revenue Growth
- ADXN N/A
- BTAI 64.20
- 52 Week Low
- ADXN $6.67
- BTAI $1.72
- 52 Week High
- ADXN $27.90
- BTAI $49.58
- Technical
- Relative Strength Index (RSI)
- ADXN 47.90
- BTAI 39.93
- Support Level
- ADXN $7.16
- BTAI $1.76
- Resistance Level
- ADXN $8.05
- BTAI $2.11
- Average True Range (ATR)
- ADXN 0.45
- BTAI 0.28
- MACD
- ADXN -0.02
- BTAI 0.02
- Stochastic Oscillator
- ADXN 51.22
- BTAI 16.98
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.